uniQure N.V. Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent
uniQure N.V. (QURE) reported Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent of -$116.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-02.
Financial Statements › Income Statement › Unrealized Gains
us-gaap:OtherComprehensiveIncomeDefinedBenefitPlansTaxPortionAttributableToParent · last filed 2026-03-02
- uniQure N.V. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax, attributable to parent for fiscal 2025 was -$116.00K.
- uniQure N.V. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax, attributable to parent for fiscal 2024 was -$57.00K, a 113.67% decline from fiscal 2023.
- uniQure N.V. other comprehensive (income) loss, defined benefit plan, after reclassification adjustment, tax, attributable to parent for fiscal 2023 was $417.00K.
| Period end | Other Comprehensive (Income) Loss, Defined Benefit Plan, after Reclassification Adjustment, Tax, Attributable to Parent 12 month |
|---|---|
| 2025-12-31 | -$116.00K 10-K · filed 2026-03-02 |
| 2024-12-31 | -$57.00K 10-K · filed 2026-03-02 |
| 2023-12-31 | $417.00K 10-K · filed 2026-03-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Immunome Inc. (IMNM) | United States | $2.538B | -9.45 |
| Disc Medicine, Inc. (IRON) | United States | $2.553B | -11.40 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 |